1. Burkholderia pseudomallei OMVs derived from infection mimicking conditions elicit similar protection to a live-attenuated vaccine
- Author
-
Jason W. Sahl, Lisa A. Morici, Chad J. Roy, Jacob P. Bitoun, Yihui Wang, Christopher Davitt, Sarah M. Baker, Joseph P. Hoffmann, James B. McLachlan, Nicole L. Kikendall, Kasi Russell Lodrigue, Paul Keim, Patrick S. Gellings, and Erik W. Settles
- Subjects
0301 basic medicine ,Melioidosis ,030106 microbiology ,Immunology ,Article ,Microbiology ,03 medical and health sciences ,Adjuvanticity ,medicine ,Pharmacology (medical) ,RC254-282 ,Pharmacology ,Vaccines ,Attenuated vaccine ,biology ,Burkholderia pseudomallei ,Intracellular parasite ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC581-607 ,biology.organism_classification ,medicine.disease ,030104 developmental biology ,Infectious Diseases ,Immunization ,bacteria ,Immunologic diseases. Allergy ,Intracellular ,CD8 - Abstract
Burkholderia pseudomallei is a Gram-negative, facultative intracellular bacillus that causes the disease melioidosis. B. pseudomallei expresses a number of proteins that contribute to its intracellular survival in the mammalian host. We previously demonstrated that immunization with OMVs derived from B. pseudomallei grown in nutrient-rich media protects mice against lethal disease. Here, we evaluated if OMVs derived from B. pseudomallei grown under macrophage-mimicking growth conditions could be enriched with intracellular-stage proteins in order to improve the vaccine. We show that OMVs produced in this manner (M9 OMVs) contain proteins associated with intracellular survival yet are non-toxic to living cells. Immunization of mice provides significant protection against pulmonary infection similar to that achieved with a live attenuated vaccine and is associated with increased IgG, CD4+, and CD8+ T cells. OMVs possess inherent adjuvanticity and drive DC activation and maturation. These results indicate that M9 OMVs constitute a new promising vaccine against melioidosis.
- Published
- 2021